1. Here Are The Prime Catalysts For Roche s Stock http://www.trefis.com/stock/rhhby/articles/288827/here-are-the-prime-catalysts-for-roches-stock/2015-04-10 by Trefis Team $RHHBY $BMY $MRK

  2. Three Biotechs that Could Radically Change the Practice of Medicine Forever: Wasatch Analyst Jill... http://www.trefis.com/stock/ino/articles/287127/three-biotechs-that-could-radically-change-the-practice-of-medicine-forever-wasatch-analyst-jill-wahleithner/2015-04-01 $INO $RHHBY $NVO

  3. What Does Recent Biosimilar Approval By The FDA Mean? http://www.trefis.com/stock/rhhby/articles/286282/what-does-recent-biosimilar-approval-by-the-fda-mean/2015-03-24 by Trefis Team $BMY $JNJ $MRK

  4. Pfizer Can Add 5%-10% Value By Streamlining Its R&D SPending http://www.trefis.com/stock/pfe/articles/285627/pfizer-can-add-5-10-value-by-streamlining-its-rd-spending/2015-03-19 by Trefis Team $PFE $BMY $RHHBY

  5. These High-Quality European Dividend Payers Could Benefit From A Rising Dollar http://www.trefis.com/stock/spy/articles/285610/these-high-quality-european-dividend-payers-could-benefit-from-a-rising-dollar/2015-03-19 $BUD $UL $RHHBY

  6. These Two Catalysts Can Move Merck s Stock Up http://www.trefis.com/stock/mrk/articles/284621/these-two-catalysts-can-move-mercks-stock-up/2015-03-12 by Trefis Team $MRK $BMY $RHHBY

  7. The Key Contributor Of Roche s Value Is Not In Danger Yet http://www.trefis.com/stock/rhhby/articles/284112/the-key-contributor-of-roches-value-is-not-in-danger-yet/2015-03-09 by Trefis Team $RHHBY $MRK $BMY

  8. Merck s Partnership With NGM Is A Bold Move http://www.trefis.com/stock/mrk/articles/282775/mercks-partnership-with-ngm-is-a-bold-move/2015-03-02 by Trefis Team $MRK $RHHBY $PFE

  9. We Are Not Surprised That J&J May Be Selling Cordis http://www.trefis.com/stock/jnj/articles/282127/we-are-not-surprised-that-jj-may-be-selling-cordis/2015-02-24 by Trefis Team $JNJ $BSX $RHHBY

  10. Merck Posts Disappointing Numbers As Experimental Hepatitis C Treatment Loses Breakt... http://www.trefis.com/stock/mrk/articles/279530/feb-6publish-todaymerck-posts-disappointing-numbers-as-experimental-hepatitis-c-treatment-loses-breakthrough-designation/2015-02-06 by Trefis Team $MRK $PFE $BMY

  11. Roche Posts Solid Numbers But All Eyes On What The Future Holds For The Company http://www.trefis.com/stock/rhhby/articles/278273/roche-posts-solid-numbers-but-all-eyes-on-what-the-future-holds-for-the-company/2015-02-02 by Trefis Team $RHHBY $PFE $MRK

  12. Merck Earnings Preview http://www.trefis.com/stock/mrk/articles/275625/merck-earnings-preview-earnings-on-4th-feb/2015-02-02 by Trefis Team $MRK $PFE $RHHBY

  13. Bristol-Myers Squibb Earnings: Currency Headwinds Take The Shine Off Encouraging New... http://www.trefis.com/stock/bmy/articles/277962/bristol-myers-squibb-earnings-currency-headwinds-take-the-shine-off-encouraging-new-drug-sales/2015-01-29 by Trefis Team $BMY $PFE $MRK

  14. Roche Earnings Preview: Oncology Drugs And Tamiflu Will Help The Revenue Growth http://www.trefis.com/stock/rhhby/articles/275728/roche-earnings-preview-oncology-drugs-and-tamiflu-will-help-the-revenue-growthearnings-on-28-jan/2015-01-26 by Trefis Team $RHHBY $JNJ $MRK

  15. Bristol-Myers Squibb Earnings Preview: Increasing Sales From New Drugs May Ease Th... http://www.trefis.com/stock/bmy/articles/275448/bristol-myers-squibb-earnings-preview-increasing-sales-from-new-drugs-may-ease-the-pressure-off-revenue-growth-earnings-on-27-jan/2015-01-23 by Trefis Team $BMY $MRK $RHHBY

  16. How Roche Will Perform In 2015? http://www.trefis.com/stock/rhhby/articles/273912/how-roche-will-perform-in-2015/2015-01-09 by Trefis Team $RHHBY $JNJ $PFE

  17. What 2015 Will Bring For Bristol-Myers Squibb http://www.trefis.com/stock/bmy/articles/273537/what-2015-will-bring-for-bristol-myers-squibb/2015-01-07 by Trefis Team $BMY $MRK $RHHBY

  18. The Year 2014 In Review: How Johnson & Johnson Became More Pharma Focused http://www.trefis.com/stock/jnj/articles/271038/the-year-2014-in-review-how-johnson-johnson-became-more-pharma-focused/2014-12-29 by Trefis Team $JNJ $RHHBY $PFE

  19. Weekly Pharmaceutical Notes: Pfizer, Bristol-Myers Squibb And Roche http://www.trefis.com/stock/mrk/articles/272438/weekly-pharmaceutical-notes-pfizer-bristol-myers-squibb-and-roche/2014-12-26 by Trefis Team $RHHBY $PFE $MRK

  20. Roche s Double Drug Failure Is Meaningful http://www.trefis.com/stock/rhhby/articles/272136/roches-double-drug-failure-is-meaningful/2014-12-24 by Trefis Team $RHHBY $BMY $MRK

  21. Roche Hopes For Melanoma Therapy Approval http://www.trefis.com/stock/rhhby/articles/269983/roche-hopes-for-melanoma-therapy-approval/2014-12-17 by Trefis Team $RHHBY $MRK $BMY

  22. Brinson Patrick s Christopher S. James: All Catalysts Are Not Created Equal http://www.trefis.com/stock/rgls/articles/268638/brinson-patricks-christopher-s-james-all-catalysts-are-not-created-equal/2014-12-08 $RGLS $RHHBY

  23. Roche s Expands Diagnostics Position With The Acquisition Of Ariosa http://www.trefis.com/stock/rhhby/articles/268459/roches-expands-diagnostics-position-with-the-acquisition-of-ariosa/2014-12-04 by Trefis Team $RHHBY $BSX $JNJ

  24. Weekly Pharmaceutical Notes: Pfizer, Johnson & Johnson, Bristol-Myers Squibb And Roche http://www.trefis.com/stock/pfe/articles/266661/weekly-pharmaceutical-notes-pfizer-johnson-johnson-bristol-myers-squibb-and-roche/2014-11-21 by Trefis Team $PFE $JNJ $BMY

  25. Roche s Avastin Gets Approval For Ovarian Cancer, But Incremental Revenues Will Be... http://www.trefis.com/stock/rhhby/articles/266345/roches-avastin-gets-approval-for-ovarian-cancer-but-incremental-revenues-will-be-small/2014-11-20 by Trefis Team $RHHBY $BMY $MRK